# Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

> **NCT04789915** · PHASE1 · RECRUITING · sponsor: **Bjorn H. Ebdrup** · enrollment: 46 (estimated)

## Conditions studied

- Psychosis
- Negative Symptoms With Primary Psychotic Disorder

## Interventions

- **DRUG:** Memantine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04789915
- **Lead sponsor:** Bjorn H. Ebdrup
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-26
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789915, "Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04789915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*